AUPH News and Press, Aurinia Pharmaceuticals Inc From 04/12/19

Aurinia Pharmaceuticals ( AUPH -2.9% ) appoints Peter Greenleaf as CEO of the company and Director More news on: Aurinia Pharmaceuticals Inc., Healthcare stocks news, Read more ...

Appointments effective as of April 29, 2019 Dr. Richard M. Glickman to retire from executive and board roles and remain an advisor to the Company for one year Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”), a l...

Motif Bio plc (NASDAQ: MTFB ) +55%  on iclaprim meeting with FDA. More news on: Motif Bio plc, China Bat Group, Inc., Nevro Corp., Stocks on the move, Read more ...

Aurinia Pharmaceuticals, Inc. (AUPH) Q4 2018 Results Earnings Conference Call March 19, 2019 04:30 PM ET Company Participants Dr. Glenn Schulman - Investor Relations Dr. Richard Glickman - Chief Executive Officer Dennis Bourgeault - Chief Financial Officer Neil Solomons - Ch...

Aurinia Pharma (NASDAQ: AUPH ): Q4 GAAP EPS of -$0.17 in-line. Revenue of $0.03M in-line (flat Y/Y). Press Release More news on: Aurinia Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news,

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today reported its financial results for the fourth quarter and year ended December 31, 2018. Amounts, unless specified otherwise, are expressed in U.S. dollars. 2018 and Rece...

In recognition of World Kidney Day and National Kidney Month, Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP), a late clinical-stage biopharmaceutical company with research ongoing in two kidney diseases, Lupus Nephritis (LN) and Focal Segmental Glomerulosclerosis (FSGS), today announce...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that it will release its fourth quarter and full year 2018 financial results on Tuesday, March 19, 2019, after the market closes. Aurinia’s management team will host a conference call ...

Background on Aurinia Pharmaceuticals Aurinia Pharmaceuticals ( AUPH ) is a small late-stage pharmaceutical company based out of British Colombia. They are currently conducting a large phase III trial testing their novel calcineurin inhibitor, Voclosporin, in the treatment of Lupus Nephri...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (the “ Company ”) today announced that, further to its Open Market Sale Agreement with Jefferies LLC previously disclosed on November 30, 2018, in relation to at-the-market (“ATM”) offerings of common shares in ...